The CYP2D6 enzyme handles roughly 25% of all prescribed medications, including opioid pain relievers, antidepressants, antipsychotics, and the breast cancer drug tamoxifen. Most people carry at least one functional copy of CYP2D6, but a small subset carry rare variants that prevent any enzyme from being made at all. rs28371733 is one such variant — a stop-gain mutation¹¹ stop-gain mutation
also called a nonsense mutation; the codon change creates a premature termination signal that truncates the CYP2D6 protein before it can fold into a working enzyme.

This variant is most prevalent in people of African ancestry (allele frequency ~0.86%), where it is approximately 90 times more common than in Europeans (<0.01%). This ancestry-skewed distribution means that African-descent patients are disproportionately at risk of being unrecognised poor metabolisers — a gap that matters enormously when codeine, tramadol, or psychiatric medications are prescribed without pharmacogenomic testing.

The Mechanism

rs28371733 introduces a T at genomic position chr22:42,126,914 (GRCh38) on the plus strand. Because CYP2D6 is transcribed from the minus strand, this corresponds to a c.1252G>T change in the coding sequence (NM_000106.6), converting codon 418 from GAA (glutamic acid) to TAA (stop). The result is a premature termination codon²² premature termination codon
the ribosome reaches the stop signal at position 418 and releases an incomplete 417-amino-acid peptide, which is rapidly degraded rather than folding into active enzyme. With no functional enzyme produced, CYP2D6 activity score is 0.

This is mechanistically distinct from the more common decreased-function alleles (*10, *41) — those reduce enzyme output gradually through splicing or altered catalytic rate. A stop-gain abolishes output entirely. Carriers of this variant on one allele paired with another no-function allele (such as *4 or *6) are classified as CYP2D6 poor metabolizers³³ CYP2D6 poor metabolizers
activity score = 0; the CPIC standard phenotype assignment for individuals whose combined CYP2D6 activity across both alleles equals zero.

The Evidence

The 2021 CPIC guideline for CYP2D6 and opioids⁴⁴ CPIC guideline for CYP2D6 and opioids
Clinical Pharmacogenetics Implementation Consortium — the authoritative body that translates pharmacogenomic evidence into clinical dosing guidance provides strong-level recommendations for CYP2D6 poor metabolizers: avoid codeine and tramadol because both are prodrugs requiring CYP2D6 to produce their active analgesic metabolites (morphine and O-desmethyltramadol, respectively). A poor metabolizer cannot complete this conversion, resulting in treatment failure rather than analgesia.

For antidepressants and antipsychotics, the 2015 CPIC SSRI guideline⁵⁵ 2015 CPIC SSRI guideline
covers fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline; updated recommendations available at PharmGKB recommends selecting alternative drugs not predominantly metabolized by CYP2D6, or reducing standard starting doses by 50% and titrating slowly, for poor metabolizers. Drugs like paroxetine, fluvoxamine, and atomoxetine accumulate to toxic levels without CYP2D6 clearance.

Population-level studies confirm the clinical relevance: a systematic review of 172 studies across 44,572 individuals⁶⁶ 172 studies across 44,572 individuals
Llerena et al. 2015 established that CYP2D6 no-function allele frequency varies substantially by ancestry, underscoring the need for ancestry-aware pharmacogenomic testing. African and admixed populations carry a distinct profile of no-function alleles compared to Europeans, meaning European-biased genotyping panels may miss relevant variants in these groups.

Practical Implications

If you carry the T allele at rs28371733 paired with another no-function CYP2D6 allele, your combined CYP2D6 activity score is 0, placing you in the poor metabolizer category. All CYP2D6 prodrugs (codeine, tramadol) are ineffective for pain relief. All drugs cleared by CYP2D6 (most antidepressants, antipsychotics, atomoxetine, tamoxifen, metoprolol) will accumulate to higher-than-expected levels, increasing side effect and toxicity risk.

The key clinical action is to inform every prescriber of your CYP2D6 status. Emergency settings are the highest-risk environment, because codeine and tramadol are frequently prescribed reflexively for acute pain. Alternative opioids — morphine, hydromorphone, oxymorphone, fentanyl — do not require CYP2D6 activation and are appropriate substitutes.

Interactions

CYP2D6 metabolizer status is determined by the combination of both alleles (the diplotype). A single T allele at rs28371733 paired with a normal-function allele results in intermediate or normal metabolizer status depending on what the other allele contributes. Only when paired with another no-function allele (rs3892097 /*4, rs1065852 /*6, rs5030655 /*3, or gene deletion /*5) does poor metabolizer status result.

Phenoconversion is also relevant: strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine) can further suppress residual enzyme activity. For a heterozygous carrier who is already an intermediate metabolizer, adding a CYP2D6 inhibitor can mimic poor metabolizer pharmacokinetics even without a second no-function allele.

The TCF7L2 gene holds a unique distinction in human genetics: it is the single strongest common genetic predictor of type 2 diabetes, with effects replicated across every major ethnic population studied. Two variants — rs7903146 and rs12255372 — are already well-characterized in this encyclopedia. rs290475 sits ~26,000 base pairs upstream of their coding region in intron 4, potentially tagging a distinct functional haplotype within the same gene-regulatory landscape.

The Mechanism

TCF7L2 encodes a [transcription factor | a protein that controls which genes are switched on or off by binding to specific DNA sequences] in the canonical Wnt/beta-catenin signaling pathway¹¹ Wnt/beta-catenin signaling pathway
a fundamental cell-communication cascade governing development, stem cell maintenance, and metabolic homeostasis. In the pancreatic beta cell, TCF7L2 does two critical jobs: it drives expression of the GLP-1 receptor²² GLP-1 receptor
the receptor for GLP-1, a gut hormone that potently stimulates insulin secretion after meals and regulates the beta-cell's survival via the p53 pathway. Beta cell-specific TCF7L2 knockout in mice³³ Beta cell-specific TCF7L2 knockout in mice
Mitchell et al. Selective disruption of Tcf7l2 in the pancreatic β cell impairs secretory function and lowers β cell mass. Hum Mol Genet, 2015 reduces GLP-1 receptor expression by ~40% and impairs both glucose-stimulated and GLP-1-stimulated insulin secretion.

In the liver, TCF7L2 plays an opposing but complementary role. Insulin normally upregulates hepatic TCF7L2 expression, which then acts as a brake on gluconeogenesis⁴⁴ gluconeogenesis
the liver's ability to manufacture new glucose from non-sugar precursors such as amino acids and glycerol. Knocking out hepatic TCF7L2⁵⁵ Knocking out hepatic TCF7L2
Ip et al. AJP Endocrinol Metab, 2012 increases glucose output, while overexpression dampens it — evidence that TCF7L2 is a direct molecular link between the Wnt pathway and fasting blood sugar.

The deep intronic position of rs290475 (c.484-26924 in the major transcript) suggests it acts as a regulatory tag — influencing nearby transcription factor binding sites, chromatin accessibility, or splice-site efficiency rather than altering the protein sequence. Intronic variants in this region of TCF7L2 have been shown to alter islet-specific enhancer activity, and rs290475 may mark a distinct regulatory element not captured by rs7903146.

The Evidence

rs290475 has no direct type 2 diabetes GWAS entry in the GWAS Catalog as of 2026. Its most prominent documented associations — identified via proxy analysis — are with bipolar disorder in the context of elevated BMI⁶⁶ bipolar disorder in the context of elevated BMI
Winham et al. Genome-wide association study of bipolar disorder accounting for effect of body mass index identifies a new risk allele in TCF7L2. Mol Psychiatry, 2014 and with neuroticism conditioned on educational/cognitive phenotypes. This is a hallmark of pleiotropic TCF7L2 variants — the Wnt pathway governs both metabolic and neurodevelopmental programs, and intronic regulatory variants can produce tissue-specific expression effects that manifest differently in brain versus pancreas versus liver.

The broader TCF7L2 locus literature documents the mechanism clearly: risk allele carriers show impaired incretin-mediated insulin secretion⁷⁷ risk allele carriers show impaired incretin-mediated insulin secretion
Florez et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. NEJM, 2006, reduced beta cell mass, and increased hepatic glucose output. A global meta-analysis of 17,000+ T2D cases⁸⁸ global meta-analysis of 17,000+ T2D cases
Cauchi et al. J Mol Med, 2007 established the TCF7L2 locus OR of 1.46 — the largest effect size for any common T2D variant. Because rs290475 tags this same regulatory region, its C-allele carriers may share a portion of that risk through a haplotype distinct from the primary rs7903146 signal, but direct confirmation awaits fine-mapping studies with phenotyped T2D cohorts.

Practical Actions

The evidence for rs290475-specific dietary guidance is indirect, extrapolated from the broader TCF7L2 locus and GLP-1/hepatic mechanism. If you carry the C allele, the most relevant actions target:

1. Incretin optimization — meals and foods that stimulate GLP-1 secretion most effectively (high-fiber, low-glycemic-index foods; legumes; fermented dairy) support the impaired GLP-1 signaling pathway.
2. Hepatic glucose management — spreading carbohydrate intake across multiple smaller meals reduces peak gluconeogenic stimulus and leverages the meal-responsive TCF7L2/Wnt axis in the liver.
3. Metabolic monitoring — given the locus-level evidence for T2D risk, periodic fasting glucose and HbA1c checks are prudent, especially as a complement to rs7903146 and rs12255372 results.

Interactions

This variant co-localizes with rs7903146 and rs12255372 in the TCF7L2 regulatory haplotype block. Carriers of C at rs290475 who also carry T at rs7903146 represent a subset with potential additive or independent effects on TCF7L2 expression levels in pancreatic islets and liver. Future fine-mapping studies at this locus may resolve whether rs290475 tags an independent causal variant or is in partial LD with the primary signal.

The PER2 gene encodes Period Circadian Regulator 2¹¹ Period Circadian Regulator 2
One of three Period proteins forming the core negative feedback arm of the mammalian circadian clock, suppressing CLOCK:BMAL1-driven transcription, one of the master gears of your internal 24-hour clock. PER2 protein accumulates during the day, enters the nucleus, and shuts down the CLOCK:BMAL1 transcription complex — resetting the cycle. The rs35333999 variant changes a valine to isoleucine at position 903, in a region that overlaps a predicted interaction interface with PPARG²² predicted interaction interface with PPARG
The nuclear receptor involved in adipogenesis and metabolic regulation, suggesting a link between circadian timing and metabolism.

This variant is notable because it is the strongest association signal that peaks directly within a core circadian clock gene in genome-wide association studies of chronotype³³ genome-wide association studies of chronotype
Jones et al. identified rs35333999 in 100,420 UK Biobank participants at P=10^-8, later replicated at P=9.7x10^-14 in 335,789 individuals. Most chronotype GWAS signals map to regulatory or intergenic regions — PER2 V903I is a coding change in the heart of the clock machinery.

The Mechanism

The V903I substitution alters a conserved valine in exon 19 of the canonical PER2 transcript. Computational analysis predicts this change as probably damaging⁴⁴ Computational analysis predicts this change as probably damaging
PolyPhen-2 score of 0.963, indicating high likelihood of functional impact. The valine-to-isoleucine change is conservative (both are hydrophobic branched-chain amino acids), but the position is conserved across mammalian species⁵⁵ conserved across mammalian species
suggesting functional constraint at this site, and the V903 residue sits at a predicted protein-protein interaction interface.

The functional consequence is a measurable lengthening of intrinsic circadian period — the fundamental oscillation speed of the molecular clock. A longer period means the clock "runs slow," requiring more environmental resetting (via light) each day to stay synchronized with the 24-hour world. When the clock runs slow, the natural tendency is to drift later — later sleep onset, later wake time, and a preference for evening activity.

The Evidence

The key study establishing both population-level chronotype association and mechanistic causation was Chang et al. 2019⁶⁶ Chang et al. 2019
Chang A-M et al. Chronotype Genetic Variant in PER2 is Associated with Intrinsic Circadian Period in Humans. Sci Rep, 2019. This study combined large-scale GWAS data with precisely controlled laboratory measurements:

In the UK Biobank cohort of 335,789 individuals⁷⁷ UK Biobank cohort of 335,789 individuals
unrelated participants of European ancestry, the T allele reached genome-wide significance for self-reported eveningness (P = 9.7 x 10^-14, beta = 0.058). This replicated and strengthened the earlier signal from Jones et al. 2016⁸⁸ Jones et al. 2016
in 100,420 UK Biobank participants at P = 10^-8.

The same study then measured intrinsic circadian period in a subset of participants under highly controlled forced desynchrony protocols⁹⁹ forced desynchrony protocols
Laboratory protocols where participants live on non-24-hour schedules to unmask the endogenous circadian period from environmental time cues. T allele carriers showed a 12-minute longer circadian period by both core body temperature¹⁰¹⁰ core body temperature
24.34 +/- 0.17 h vs 24.14 +/- 0.20 h, P = 0.030 and plasma melatonin¹¹¹¹ plasma melatonin
24.34 +/- 0.18 h vs 24.15 +/- 0.19 h, P = 0.039 measurements. The variant accounted for approximately 7% of inter-individual variance in circadian period — a substantial effect for a single SNP.

The expanded chronotype GWAS of 697,828 individuals¹²¹² expanded chronotype GWAS of 697,828 individuals
Jones et al. 2019 confirmed PER2 as one of 351 loci associated with chronotype, and identified enrichment in circadian rhythm pathways, retinal light-sensing, and insulin signaling.

Practical Implications

A 12-minute longer circadian period may sound small, but it compounds daily. Without sufficient morning light exposure to reset the clock each day, carriers drift progressively later. This has real consequences for metabolic health: evening chronotypes consistently show higher rates of type 2 diabetes, obesity, and cardiovascular disease in epidemiological studies, driven by late eating, disrupted meal-activity synchronization, and social jet lag.

The overlap of the V903I position with a predicted PPARG interaction interface is intriguing. PPARG is a key regulator of adipocyte differentiation and insulin sensitivity. If V903I alters PER2-PPARG interaction, it could directly link circadian period length to metabolic outcomes — though this protein-protein interaction has not yet been confirmed experimentally.

Interactions

PER2 V903I interacts functionally with other circadian clock gene variants. The CLOCK rs1801260 G allele increases CLOCK protein levels, potentially amplifying PER2 expression; combined with a PER2 variant that slows the clock, the result could be additive circadian delay. Similarly, PER3 rs228697 (Pro864Ala) and PER3 rs10462020 (Val647Gly) affect the Period protein arm of the same feedback loop. Carriers of multiple evening-shifting alleles across PER2, PER3, and CLOCK likely experience more pronounced circadian delay than any single variant predicts.

Compound implication for PER2 rs35333999 + CLOCK rs1801260: Individuals carrying both the PER2 T allele (CT or TT) and the CLOCK G allele (AG or GG) may experience compounded evening-shifting effects — both increased CLOCK protein driving the positive limb and a slowed PER2 negative feedback loop. These carriers would benefit most from aggressive morning light exposure and strict meal timing.

PPARG (peroxisome proliferator-activated receptor gamma) is the master regulator of adipogenesis¹¹ Adipogenesis: the differentiation of precursor cells into mature fat-storing adipocytes. PPARG is required for this process — without it, adipocytes cannot form. and a central hub for insulin sensitivity. It is the molecular target of thiazolidinedione drugs²² Thiazolidinediones such as pioglitazone and rosiglitazone directly activate PPARG to improve insulin sensitivity in type 2 diabetes — making PPARG variants especially relevant for predicting drug response. used to treat type 2 diabetes. The rs3856806 variant (C1431T, His477His) sits in exon 6 of PPARG and does not change the histidine amino acid at position 477 — but it does affect how the gene is expressed, making it one of the most studied PPARG variants in metabolic disease genetics.

The Mechanism

Although His477His produces no amino acid change, the C-to-T substitution is not biologically neutral. The T allele is thought to alter mRNA ³³ mRNA processing: synonymous variants can shift splicing efficiency, change mRNA stability, or alter the rate of codon translation, all without changing the protein sequence. processing in a way that modestly increases adipocyte differentiation capacity. More differentiated adipocytes tend to be smaller and more insulin-sensitive, which may explain the T allele's associations with improved glucose metabolism and lipid profiles. The C1431T variant shows stronger linkage disequilibrium with the PPARG haplotype block associated with metabolic outcomes than the Pro12Ala (rs1801282) variant in the same gene, and in some populations it is a better predictor of fasting insulin levels and insulin resistance than Pro12Ala alone.

The Evidence

A meta-analysis of 9 studies⁴⁴ meta-analysis of 9 studies
Tiongco et al. Association of the rs3856806 Polymorphism in the PPARG Gene with T2DM: A Meta-Analysis of 11,811 Individuals. Lab Med, 2023 encompassing 11,811 individuals found that carrying the T allele significantly reduces type 2 diabetes risk (allelic model OR 0.82; 95% CI 0.76–0.89; P < .00001), with consistent results across co-dominant, dominant, and recessive models.

A separate meta-analysis of 33 studies⁵⁵ meta-analysis of 33 studies
Li et al. G Allele of rs1801282 Confers Increased Risk of Obesity; T Allele of rs3856806 Displays Protective Role Against Dyslipidemia. Front Endocrinol, 2022 covering 18,353 subjects found that T allele carriers had meaningfully lower LDL-cholesterol (SMD −0.09 mmol/L; 95% CI −0.15 to −0.03; p < 0.01) and higher HDL-cholesterol (SMD +0.06 mmol/L; 95% CI 0.02 to 0.10; p < 0.01) compared to CC homozygotes. Importantly, this meta-analysis found no significant association between rs3856806 and BMI when examined in isolation.

A haplotype study⁶⁶ haplotype study
Valve et al. Haplotype analysis of PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet, 2002 in over 1,700 individuals (including 1,107 type 2 diabetics) clarified an important nuance: when C1431T and Pro12Ala are analyzed together as haplotypes, they have opposing effects on body weight. The common Pro-C haplotype is the neutral baseline. The Ala-C haplotype (Ala12 + C1431) is weight-protective, while the Pro-T haplotype (Pro12 + T1431) carries an increased BMI (β = +2.9 kg/m²; p = 0.002). This explains why studies examining C1431T alone find inconsistent BMI results — the T allele co-segregates with Pro12 in ~70% of carriers.

A Japanese cohort study⁷⁷ Japanese cohort study
Nakashima et al. PPARγ2 C1431T genotype increases metabolic syndrome risk in young men with low cardiorespiratory fitness. Physiol Genomics, 2011 in 716 adults found that CC genotype combined with low cardiorespiratory fitness significantly increased metabolic syndrome risk in men under 40, while higher fitness levels attenuated the genetic difference between CC and T-allele carriers.

Practical Implications

The T allele (present in approximately 22% of Europeans as CT heterozygotes and 2% as TT homozygotes) is associated with a more favorable metabolic profile — lower LDL-C, higher HDL-C, and reduced T2D risk. For CC homozygotes (~76% of people of European descent), cardiorespiratory fitness is especially actionable: low fitness amplifies the absence of the T allele's protective effects, particularly in younger men. Monitoring lipid and glucose trends is useful for CC carriers to detect early metabolic drift that T allele carriers are less susceptible to.

Interactions

The key interaction for this variant is with rs1801282 (Pro12Ala) in the same PPARG gene. These two variants form haplotypes with opposing effects: the Ala-C haplotype (rs1801282 G + rs3856806 C) is weight-protective, while the Pro-T haplotype (rs1801282 C + rs3856806 T) modestly increases BMI despite the T allele's metabolic benefits. CC carriers of rs3856806 on the Pro12 background represent the population-typical neutral haplotype. The rs17036314 variant (PPARG intron 2) compounds with physical activity to further modify T2D risk in individuals with impaired glucose tolerance.

Cholesteryl ester transfer protein (CETP) is the molecular shuttle that moves cholesterol esters from HDL to LDL and VLDL, simultaneously transferring triglycerides in the opposite direction. This exchange is a central step in reverse cholesterol transport — the process by which excess cholesterol is harvested from peripheral tissues and returned to the liver for excretion. High CETP activity tends to lower HDL levels and shrink HDL particle size; low CETP activity allows HDL to accumulate as larger, more cholesterol-rich particles.

The I405V variant at rs5882 sits in exon 14 of the CETP gene¹¹ exon 14 of the CETP gene
located on chromosome 16q13, encoding a 476-amino-acid secreted glycoprotein. Unlike the TaqIB variant (rs708272), which is a non-functional intronic marker in linkage with the functional haplotype, I405V is a direct coding change — substituting isoleucine (Ile) for valine (Val) at mature-protein position 405 (precursor position 422). This direct amino acid substitution reduces CETP secretion from hepatocytes and lowers circulating CETP protein levels.

The Mechanism

At the molecular level, the Val allele (G on the plus strand) reduces CETP protein expression. Carriers of the Val allele have measurably lower serum CETP concentrations: in the original Barzilai cohort, VV centenarians showed CETP levels of 1.73 ± 0.11 μg/mL vs 2.12 ± 0.10 μg/mL in Ile carriers (p=0.01)²² CETP levels of 1.73 ± 0.11 μg/mL vs 2.12 ± 0.10 μg/mL in Ile carriers (p=0.01). Lower CETP activity allows HDL particles to retain their cholesteryl ester cargo longer, producing larger, more buoyant HDL2 particles and elevating total HDL-C. Studies suggest VV carriers tend to have higher HDL-C levels, with the effect more pronounced in women.

The relationship between I405V and cognitive health has a plausible mechanism: HDL particles deliver cholesterol to the brain through the blood–brain barrier, and larger, lipid-rich HDL particles may support neuronal membrane integrity and myelin maintenance. Reduced CETP activity may also lower apolipoprotein B–containing particles in cerebrospinal fluid, decreasing amyloid deposition.

The Evidence

The landmark study was Barzilai et al., JAMA 2003³³ Barzilai et al., JAMA 2003, which genotyped 213 Ashkenazi Jewish centenarians (mean age 98.2 years), 216 of their offspring, and 258 age-matched controls. Centenarians and their offspring showed 2.9- to 3.6-fold enrichment (in men) and 1.5- to 2.7-fold enrichment (in women) for the VV genotype compared to controls, alongside larger HDL and LDL particle sizes, lower hypertension prevalence, and lower rates of metabolic syndrome.

The longevity-cognition link was formalized in Barzilai et al., Neurology 2006 ⁴⁴ Barzilai et al., Neurology 2006 : among cognitively intact centenarians (MMSE >25), 29% were VV vs only 14% of those with MMSE ≤25 (p=0.02). In a younger cohort (Einstein Aging Study), VV subjects showed a fivefold increase compared to expected frequency. The most quantitatively precise evidence comes from Sanders et al. 2010⁵⁵ Sanders et al. 2010: following 523 older adults for a mean 4.3 years, VV homozygotes showed significantly slower memory decline (p=0.03) and dramatically lower dementia risk (HR 0.28, 95% CI 0.10–0.85, p=0.02) and Alzheimer's disease risk (HR 0.31, 95% CI 0.10–0.95, p=0.04). The large Cache County Study⁶⁶ Cache County Study, with 4,486 subjects followed over 12 years, found each additional Val allele associated with 0.6-point/year slower cognitive decline (p=0.011).

Importantly, this picture is not universal. Yu et al. 2012⁷⁷ Yu et al. 2012 found the opposite in 1,384 European-ancestry participants: VV genotype was associated with faster cognitive decline and higher AD risk (HR 1.63). A Chinese case-control meta-analysis ⁸⁸ Chinese case-control meta-analysis across 8 studies found the V allele was protective in Ashkenazi Jews (OR 1.46) but a risk allele in East Asian populations (OR 0.67). The APOE interaction⁹⁹ APOE interaction may partly explain this: in APOE ε4 carriers, the V allele associates with preserved cortical thickness; in non-carriers, the I allele is protective. The cardiovascular evidence is similarly mixed — the Val allele reliably raises HDL but does not consistently reduce cardiovascular events, mirroring failures of CETP inhibitor drugs in clinical trials.

Practical Actions

For GG (VV) carriers, the primary implication is the established HDL-raising effect: monitor HDL particle size (not just HDL-C) to confirm the phenotypic benefit, and support it through dietary choices known to synergize with endogenous CETP inhibition. Plant sterols (2 g/day) significantly lower triglycerides in GG individuals specifically, with no effect in other genotypes — making this a targeted dietary intervention. Niacin also raises HDL and reduces CETP activity, potentially amplifying the GG genotype's effect.

For AA (II) carriers, HDL-C and HDL particle size are worth monitoring, as higher CETP activity tends to produce smaller, denser HDL particles. Dietary strategies that modulate CETP activity — plant sterols, omega-3 fatty acids, moderate alcohol avoidance — may partially compensate for the higher CETP burden.

Interactions

The most clinically relevant interaction is with APOE genotype. The APOE ε4 allele independently raises Alzheimer's disease risk and alters lipid metabolism. In APOE ε4 carriers, the CETP Val allele appears to protect against medial temporal lobe atrophy; in non-carriers, the Ile allele is paradoxically protective. This complex interaction suggests that CETP I405V genotype should be interpreted alongside APOE status, and the net effect on neurological risk depends substantially on APOE background.

The rs708272 TaqIB variant (in the heart-inflammation category) is in strong linkage disequilibrium with rs5882 in European populations, and these two markers tag the same functional haplotype. Both should not be used simultaneously to predict CETP activity — I405V (rs5882) is the direct functional variant, while TaqIB is a proxy.

GABPB1 encodes the beta subunit of the GA-binding protein transcription factor¹¹ GA-binding protein transcription factor
Also known as Nuclear Respiratory Factor 2 (NRF2), a master regulator of mitochondrial biogenesis, one of the most important genetic determinants of aerobic capacity. NRF2 activates the genes encoding cytochrome c oxidase and other oxidative phosphorylation machinery²² cytochrome c oxidase and other oxidative phosphorylation machinery
The protein complexes in the inner mitochondrial membrane that produce ATP, essentially controlling how many and how efficient your mitochondria become in response to endurance training.

The rs7181866 variant sits in an intronic region of GABPB1 on chromosome 15. While intronic, this SNP has been consistently associated with elite athletic performance in multiple populations. The minor G allele is overrepresented in world-class endurance athletes and combat-sport athletes³³ overrepresented in world-class endurance athletes and combat-sport athletes
Combat sports require intermittent high-intensity efforts that closely mirror the metabolic demands of interval training, particularly those competing at the international level. Carriers of the AG genotype show superior training adaptations in running economy⁴⁴ training adaptations in running economy
The oxygen cost of running at a given speed—a key predictor of endurance performance compared to AA homozygotes.

The Mechanism

rs7181866 is located in intron 3 of the GABPB1 gene at chromosome 15q21.2. The A-to-G substitution affects gene regulation through mechanisms that remain under investigation, but the AG genotype may induce greater gene transcription and higher protein mRNA expression⁵⁵ AG genotype may induce greater gene transcription and higher protein mRNA expression
Possibly through altered splicing efficiency or regulatory element binding.

GABPB1 forms a heterotetramer with GABPA (the DNA-binding alpha subunit) to create the functional NRF2 transcription factor complex. This complex binds to promoter regions of nuclear-encoded mitochondrial genes⁶⁶ binds to promoter regions of nuclear-encoded mitochondrial genes
Including genes for all five oxidative phosphorylation complexes, mitochondrial transcription factor A (TFAM), and components of the mitochondrial import machinery, coordinating the nuclear control of mitochondrial function.

The NRF2 pathway is activated by endurance exercise and works in concert with PGC-1α⁷⁷ PGC-1α
PPARGC1A, the master regulator of mitochondrial biogenesis that responds to metabolic stress signals like AMPK activation and calcium. While PGC-1α acts as the signal amplifier responding to exercise, NRF2 is the downstream effector that actually turns on mitochondrial genes. Together they drive the increase in mitochondrial mass, respiratory capacity, and ATP production that defines endurance adaptation.

The Evidence

The association between rs7181866 and athletic performance has been replicated across multiple ethnic groups and sports. A 2009 Israeli study of 155 athletes and 240 controls⁸⁸ 2009 Israeli study of 155 athletes and 240 controls
Including 20 elite endurance athletes who represented Israel at world championships or Olympics found the AG genotype was significantly more frequent in endurance athletes compared to sprinters (p=0.014) and controls (p=0.0008). Critically, within the endurance group, the G allele was more frequent in elite versus national-level athletes (p=0.047), suggesting a dose-response relationship with performance level.

A 2013 Polish study of 55 male rowers⁹⁹ 2013 Polish study of 55 male rowers
Including 30 elite and 25 non-elite rowers found the G allele frequency was 5.5% in rowers versus 1.2% in sedentary controls (p=0.014). The AG genotype appeared in 10.9% of all rowers but only 2.3% of controls (p=0.012).

The variant's effect extends beyond traditional endurance sports. A 2021 Brazilian study of 164 combat-sport athletes and 965 controls¹⁰¹⁰ 2021 Brazilian study of 164 combat-sport athletes and 965 controls
Including Brazilian jiu-jitsu, judo, wrestling, and mixed martial arts competitors found the G allele in 8% of athletes versus 4% of controls (p=0.003). Among world-class athletes, the frequency jumped to 10.9% (p=0.0002). Combat sports involve repeated high-intensity bursts with short recovery periods—an intermittent effort pattern that demands robust mitochondrial capacity¹¹¹¹ intermittent effort pattern that demands robust mitochondrial capacity
The ability to rapidly restore ATP and clear lactate between rounds.

Training Response

Perhaps most interesting is how rs7181866 influences training adaptations. A 2007 Chinese study examined 18 weeks of endurance training¹²¹² 2007 Chinese study examined 18 weeks of endurance training
Progressive running program in young men, with running economy measured at 12 km/h and VO₂max tested to exhaustion in the context of a three-SNP haplotype (rs12594956, rs7181866, rs8031031). Carriers of the ATG haplotype—which includes the G allele at rs7181866—showed 57.5% greater improvement in running economy compared to non-carriers (p=0.006). This suggests the variant doesn't just correlate with elite status but actively predicts who will respond best to training.

Metabolic Trade-offs

While the G allele favors mitochondrial capacity and endurance, it comes with a metabolic cost. A 2019 South Indian study of 302 individuals¹³¹³ 2019 South Indian study of 302 individuals
Including normoglycemic controls and type 2 diabetes patients with and without obesity found the G allele was significantly associated with obesity risk among T2DM subjects. The GG genotype correlated positively with inflammatory markers (TNF-α, IL-6, leptin) and negatively with adiponectin, suggesting the enhanced mitochondrial biogenesis capacity might be coupled to altered metabolic regulation in sedentary populations.

This pattern isn't uncommon in athletic variants. The same genetic machinery that supports high-intensity training may increase vulnerability to metabolic dysfunction in the absence of regular exercise—a phenomenon sometimes called "athlete's genes in a couch potato's body"¹⁴¹⁴ "athlete's genes in a couch potato's body".

Practical Actions

If you carry the AG genotype, your genetic profile suggests superior mitochondrial training response, particularly for intermittent and endurance exercise. You're likely to see greater gains in running economy, lactate threshold, and VO₂max from consistent aerobic training compared to AA carriers. High-intensity interval training (HIIT) may be especially effective given the variant's association with combat sports.

However, the obesity association in sedentary populations means this genotype demands regular physical activity. Your mitochondrial machinery is built for use— when inactive, it may contribute to metabolic dysregulation. Prioritize consistent endurance or interval training to capitalize on your genetic advantage while mitigating metabolic risk.

Interactions

rs7181866 is in strong linkage disequilibrium¹⁵¹⁵ linkage disequilibrium
Two genetic variants inherited together due to proximity on the chromosome; D'=1, r²=0.903 with rs8031031, another GABPB1 intronic variant associated with endurance. These SNPs form haplotypes that have been studied as combinations rather than isolated variants. The most extensively studied is the ATG haplotype of rs12594956 (A), rs7181866 (G), and rs8031031 (T), which shows the strongest association with training response.

GABPB1/NRF2 works downstream of PPARGC1A (PGC-1α, rs8192678)¹⁶¹⁶ PPARGC1A (PGC-1α, rs8192678)
The Gly482Ser variant in PGC-1α has been linked to endurance athlete status and training response in multiple studies in the mitochondrial biogenesis pathway. If you carry favorable variants in both genes— PGC-1α as the exercise-responsive signal amplifier and NRF2 as the transcriptional effector—you may see additive or synergistic effects on aerobic capacity. Conversely, a mismatch (e.g., favorable PGC-1α but less responsive NRF2) could create a bottleneck where the signal is strong but the downstream machinery limits adaptation.

The variant may also interact with ACTN3 R577X (rs1815739)¹⁷¹⁷ ACTN3 R577X (rs1815739)
The "sprint gene" that determines presence of alpha-actinin-3 in fast-twitch fibers. ACTN3 XX individuals lack alpha-actinin-3 and show a shift toward aerobic metabolism—they may benefit even more from favorable NRF2 variants since their muscle fiber phenotype already favors endurance. Conversely, ACTN3 RR individuals with GABPB1 AG may represent the genetic profile for middle-distance or combat sports that blend power and endurance.

At position 5q31.1, squeezed between the DNA-repair gene RAD50¹¹ RAD50
RAD50 double-strand break repair protein; at this locus the gene's introns house regulatory elements controlling adjacent cytokine genes and the cytokine gene IL13²² IL13
Interleukin-13; a Th2 cytokine secreted by mast cells, basophils, and activated CD4+ T cells that drives IgE class switching, mucus hypersecretion, and smooth-muscle hyperresponsiveness, sits one of the most replicated immune-regulation loci in the human genome. GWAS studies have repeatedly flagged this region — designated 5q31 (RAD50-IL13 and IL4) — as a major determinant of total serum IgE levels and susceptibility to the full spectrum of atopic march³³ atopic march
the stereotyped progression from early-childhood eczema through food allergy, then asthma, then allergic rhinitis; driven by a shared Th2-skewed immune baseline that successive allergen exposures progressively unmask conditions. rs2040704 is an intronic variant in this regulatory hub — the G allele tags a chromatin state that amplifies Th2 cytokine output, raising IgE and lowering the threshold for allergic sensitization at every stage of the march.

The Mechanism

The intergenic space between RAD50 and IL13 is not empty. It contains the TH2 locus control region (TH2-LCR)⁴⁴ TH2 locus control region (TH2-LCR)
a cluster of DNase I hypersensitive sites (RHS4–RHS7) that act as long-range enhancers coordinating simultaneous IL-4, IL-5, and IL-13 transcription in activated Th2 cells; analogous to the beta-globin LCR — a collection of regulatory enhancer elements (RHS4–RHS7) that loop chromosomally to simultaneously activate IL-4, IL-5, and IL-13 when a T cell commits to the Th2 lineage. The rs2040704 G allele sits within this control region and tags a regulatory haplotype that alters DNA methylation at the IL13 promoter and modulates the expression of both IL13 and IL4 in an allele-specific manner — as demonstrated by Schieck et al. (2014), who showed allele-specific methylation differences at the TH2-LCR element RHS7⁵⁵ allele-specific methylation differences at the TH2-LCR element RHS7
Schieck M et al. Allergy 2014; rs2240032 in RHS7 shows allele-dependent methylation in cord blood and at 4.5 years, influencing downstream IL13 promoter methylation tracking from cord blood through early childhood.

When the enhancer hub is in the more active state tagged by the G allele, T cells that encounter allergens produce higher pulses of IL-13 and IL-4. IL-13 then acts directly on airway epithelium and smooth muscle — bypassing the IgE-mast-cell axis — to drive mucus hypersecretion, goblet-cell metaplasia, and smooth-muscle hyperresponsiveness⁶⁶ mucus hypersecretion, goblet-cell metaplasia, and smooth-muscle hyperresponsiveness
Wills-Karp & Chiaramonte Curr Opin Pulm Med 2003; mouse models showed IL-13 alone, without eosinophils or IgE, reproduces all hallmarks of allergic asthma. Simultaneously, IL-4 drives B-cell class switching to IgE. Higher ambient IgE sensitizes mast cells systemically, lowering the allergen threshold for urticaria, food reactions, and nasal symptoms — the allergic phenotype spreads across organ systems.

The Evidence

The 5q31 RAD50/IL13 locus is one of only a handful of immune-regulation loci with genome-wide significance for total serum IgE in multiple large cohorts. A comprehensive genome-wide association study of severe asthma by Li et al. (2010)⁷⁷ Li et al. (2010)
Li X et al. Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions. J Allergy Clin Immunol 2010 — 473 severe asthma cases and 1,892 controls — identified multiple significant SNPs in the RAD50-IL13 region, with the leading hit rs2244012 (intronic in RAD50) reaching P=3.04×10⁻⁷. The TH2 locus control region 3' of RAD50 was separately implicated by imputed variants, placing rs2040704's neighborhood at the mechanistic heart of this signal.

Fine-mapping by Sharma et al. (2014)⁸⁸ Sharma et al. (2014)
Sharma V et al. Fine-mapping of IgE-associated loci 1q23, 5q31, and 12q13 using 1000 Genomes Project data. Allergy 2014 in more than 1,300 German children confirmed 5q31 (RAD50-IL13 and IL4) as one of three major determinants of total serum IgE. Critically, they demonstrated that carrying risk alleles at all three loci — 5q31, 1q23 (FCER1A, the high-affinity IgE receptor), and 12q13 (STAT6) — elevates IgE risk fourfold, establishing that the 5q31 signal is most clinically meaningful when interpreted in the context of the broader atopic genetic landscape.

Cross-ethnic replication came from a Chinese Han study by Jiang et al. (2017)⁹⁹ Jiang et al. (2017)
Jiang XY et al. Asian Pac J Allergy Immunol 2017 of 3,013 atopic dermatitis cases and 5,483 controls, which confirmed a 5q31 RAD50/IL13 signal (rs2158177, a neighboring variant in strong LD, OR=1.15, P=1.08×10⁻³) for atopic dermatitis. The IL13 coding variant rs20541 — which produces the Gln144Arg amino acid change that reduces IL-13's affinity for its decoy receptor IL-13Rα2 and increases bioavailability — was independently confirmed as an atopic dermatitis risk variant by Lee et al. (2020)¹⁰¹⁰ Lee et al. (2020)
Lee E et al. Ann Allergy Asthma Immunol 2020 in 1,252 cases and 2,064 controls (P<0.001 in pilot, replicated). This distinct coding variant at the same locus converges on the same pathway: more effective IL-13 signaling.

The review by Potaczek & Kabesch (2012)¹¹¹¹ Potaczek & Kabesch (2012)
Potaczek DP, Kabesch M. Clin Exp Allergy 2012 contextualizes rs2040704's locus as one of six major genomic determinants of IgE regulation, alongside FCER1A, STAT6, IL4RA, TNFRSF13C, and PYCARD. Variants at 5q31 account for IgE variation driven primarily by Th2 cytokine production capacity — a distinct mechanism from FCER1A (receptor density) or IL4RA (receptor signaling efficiency).

Practical Implications

The G allele at rs2040704 does not diagnose allergy — it lowers the threshold at which allergen exposure tips into sensitization and sustained allergic inflammation. The most actionable implications concern early detection of atopic march progression and immune modulation strategies targeted at the IL-4/IL-13 axis.

Children with the GG genotype and early eczema have elevated biological risk for progression to food allergy and asthma — early allergen introduction protocols and barrier management become particularly relevant. Adults with the G allele who have never developed overt atopy may still carry subclinically elevated IgE that sensitizes them to new allergen exposures (occupational, pet, or seasonal) faster than non-carriers.

The therapeutic relevance is also increasing: biologics targeting this exact pathway — dupilumab (anti-IL-4Rα, blocks both IL-4 and IL-13 signaling), tralokinumab (anti-IL-13), and cendakimab — are now licensed for atopic dermatitis and/or asthma. G allele carriers who develop refractory atopic disease are biologically well-matched to this drug class, since the upstream genetic fault is in IL-13/IL-4 production rather than IgE receptor density or downstream signaling efficiency.

Interactions

rs2040704 at the 5q31 locus interacts multiplicatively with rs2228570/rs731236 (VDR) — vitamin D receptor variants that modulate Th2/Treg balance — and with rs20541 (IL13 R130Q), the coding variant ~23 kb downstream that determines IL-13 bioavailability independently of this regulatory variant. The combination of elevated IL-13 production (this locus) and reduced IL-13 clearance (rs20541 G allele, which reduces affinity for the decoy receptor) is a mechanistically coherent double hit for sustained Th2 inflammation.

Carriers who also have FCER1A rs2427827 or IL4RA rs1801275 risk alleles show the fourfold IgE elevation documented by Sharma et al. — a compound atopic signature where production, clearance, receptor density, and receptor signaling are all shifted toward the allergic pole.

Within the H1 haplotype of the MAPT gene — itself a well-established risk factor for neurodegenerative diseases involving tau protein — there exists a finer level of genetic variation. The rs242557 variant tags the H1c sub-haplotype, a distinct subset of H1 that carries substantially elevated risk for progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to other H1 sub-haplotypes. This SNP adds resolution beyond the broad H1/H2 distinction captured by rs17649553, identifying individuals within the H1 majority who face the highest tau-related risk.

The Mechanism

Unlike the H1/H2 distinction — driven by a 900kb chromosomal inversion — H1c is a sub-haplotype within H1 defined by a specific combination of intronic variants including rs242557. The A allele at rs242557 tags the H1c configuration, which is associated with altered transcriptional regulation of the MAPT gene¹¹ tags the H1c configuration, which is associated with altered transcriptional regulation of the MAPT gene
The intronic variant likely affects splicing regulatory elements or transcription factor binding within the first large intron of MAPT.

A 2007 study found that the H1c haplotype specifically increases both the total level of MAPT transcripts and the proportion containing four microtubule-binding repeat domains (4R tau)²² A 2007 study found that the H1c haplotype specifically increases both the total level of MAPT transcripts and the proportion containing four microtubule-binding repeat domains (4R tau)
4R tau isoforms are the predominant component of pathological tau aggregates in PSP, CBD, and some forms of Alzheimer's disease. This mechanistic finding directly links the H1c genotype to the molecular pathology of 4R tauopathies: more total tau protein, with a higher fraction folded into the 4-repeat isoform that aggregates into neurofibrillary tangles and other tau deposits.

The Evidence

A 2017 meta-analysis of 82 case-control studies found that rs242557 (A allele) confers an odds ratio of 1.96 (95% CI 1.71–2.25) for PSP and 2.51 (95% CI 1.66–3.78) for CBD³³ A 2017 meta-analysis of 82 case-control studies found that rs242557 (A allele) confers an odds ratio of 1.96 (95% CI 1.71–2.25) for PSP and 2.51 (95% CI 1.66–3.78) for CBD
These effect sizes are among the largest identified for common variants in neurodegenerative disease risk. The CBD effect size (OR 2.51) is especially striking for a common variant, indicating that H1c roughly triples the risk of this rare condition compared to non-H1c individuals.

A 2015 GWAS of 219 CBD cases and 3,750 controls confirmed the H1c sub-haplotype marked by rs242557 as significantly associated with CBD risk (p = 7.91×10⁻⁶), and demonstrated that CBD and PSP share this genetic risk architecture⁴⁴ A 2015 GWAS of 219 CBD cases and 3,750 controls confirmed the H1c sub-haplotype marked by rs242557 as significantly associated with CBD risk (p = 7.91×10⁻⁶), and demonstrated that CBD and PSP share this genetic risk architecture
This shared genetics aligns with the clinical and neuropathological overlap between the two conditions.

For Alzheimer's disease, the H1c haplotype showed association with AD risk in two autopsy-confirmed case series (Myers et al., Human Molecular Genetics, 2005)⁵⁵ the H1c haplotype showed association with AD risk in two autopsy-confirmed case series (Myers et al., Human Molecular Genetics, 2005)
The AD association appears most relevant in APOE ε4 non-carriers, where MAPT haplotype becomes a more prominent risk factor. A 2007 quantitative trait study showed rs242557 drives the H1c association with cerebrospinal fluid tau levels in a dose-dependent manner (p = 0.002)⁶⁶ rs242557 drives the H1c association with cerebrospinal fluid tau levels in a dose-dependent manner (p = 0.002)
Higher CSF tau is a biomarker of neuronal injury and is elevated years before clinical Alzheimer's onset.

Practical Actions

The H1c genotype does not cause disease on its own — it modifies risk within a multifactorial landscape. Environmental and lifestyle factors that reduce tau hyperphosphorylation and aggregation are particularly relevant: avoiding head trauma, controlling metabolic risk factors for neurodegeneration (blood pressure, insulin resistance), and staying physically and cognitively active. No approved preventive pharmacotherapy targets tau pathology specifically in the presymptomatic period, but clinical trials of tau-targeting immunotherapies are ongoing.

Individuals carrying AA or AG genotypes at rs242557 who are also H1/H1 at rs17649553 face the combined burden of the broad H1 risk and the additional H1c refinement — neurological surveillance may be warranted if other risk factors (age, family history, additional genetic risk) are present.

Interactions

rs242557 adds independent risk stratification on top of the H1/H2 distinction captured by rs17649553. Nearly all individuals with the H1c sub-haplotype (A allele at rs242557) are also H1/H1 or H1/H2 at the broader haplotype level — these SNPs are in strong linkage disequilibrium but not perfectly correlated, so together they provide finer resolution. The rs2471738 variant (also listed among related SNPs) represents another H1 sub-haplotype marker with comparable effect sizes for PSP (OR 1.85) and CBD (OR 2.07), and may tag a partially overlapping but distinct risk subgroup.

In Alzheimer's disease, the MAPT H1c effect appears to interact with APOE status: the association is nominally significant in APOE ε4 carriers but may be more prominent in non-carriers, suggesting that H1c contributes to a distinct tauopathic path to AD independent of amyloid-driven mechanisms.

CYP3A4 is the single most consequential drug-metabolizing enzyme in the human body, responsible for the biotransformation of approximately 50% of all prescription medications¹¹ 50% of all prescription medications
The CYP3A subfamily collectively handles more clinical drugs than any other metabolic pathway. Found primarily in the liver and small intestine, CYP3A4 processes everything from immunosuppressants and statins to anticoagulants, antiepileptics, and targeted cancer therapies. When a variant reduces its activity — even modestly — the downstream effects ripple through a large fraction of pharmacological care.

The CYP3A4*18 allele, defined by the rs28371759 polymorphism (c.878T>G on the coding strand; p.Leu293Arg on the protein), substitutes a leucine with the bulkier, charged arginine at position 293. This position sits within a structurally important region of the enzyme, and multiple independent studies associate the variant with reduced catalytic activity²² multiple independent studies associate the variant with reduced catalytic activity
A 2024 systematic review of 23 studies in 2,177 epilepsy patients concluded that CYP3A4 rs28371759 is linked to reduced catalytic activity. The allele is rare globally — found in fewer than 1 in 10,000 European chromosomes — but reaches frequencies of 1–2% in East Asian populations³³ 1–2% in East Asian populations
Particularly elevated in Korean, Japanese, and Han Chinese cohorts, where it carries real clinical relevance.

The Mechanism

CYP3A4 is on the minus (coding) strand of chromosome 7. The c.878T>G change (plus-strand A>G at chr7:99,764,003 GRCh38) replaces leucine-293 with arginine. Leucine is a nonpolar, hydrophobic residue; arginine carries a positive charge and a large side chain. This radical physicochemical substitution is predicted to disrupt local protein folding⁴⁴ disrupt local protein folding
SIFT and PolyPhen-2 classify p.Leu293Arg as damaging/probably damaging in or near the enzyme's substrate-binding and heme-coordinating regions. The functional consequence is reduced intrinsic clearance of CYP3A4 substrates — carriers metabolize affected drugs more slowly than people with the common Leu293 allele.

The Evidence

Clinical evidence for rs28371759 comes primarily from East Asian cohorts, where the allele is most prevalent. A 2017 study of 183 northern Han Chinese patients⁵⁵ 2017 study of 183 northern Han Chinese patients
Liu et al. warfarin dosing study in patients with mechanical heart valve replacement found that CYP3A4 rs28371759 was independently associated with higher warfarin maintenance doses, contributing 2.5% of dose variability in multivariate regression. Since CYP3A4 plays a secondary role in warfarin S-enantiomer metabolism (CYP2C9 is primary), the variant's detection even in this context speaks to its functional impact.

A 2023 cohort study of 63 Thai NSCLC patients⁶⁶ 2023 cohort study of 63 Thai NSCLC patients
Majam et al. retrospective/prospective study of CYP450 polymorphisms and osimertinib outcomes identified rs28371759 among six SNPs significantly increasing adverse drug reaction incidence with osimertinib (a CYP3A4-metabolized EGFR inhibitor). A 2024 systematic review of carbamazepine pharmacogenetics⁷⁷ 2024 systematic review of carbamazepine pharmacogenetics
Riffi et al. 23 studies, 2,177+ epilepsy patients explicitly concluded that rs28371759 contributes to reduced catalytic activity affecting carbamazepine clearance.

Population surveys confirm the East Asian enrichment: Lee et al. 2013⁸⁸ Lee et al. 2013
CYP3A4 and CYP3A5 polymorphism screening across five ethnic groups found the highest minor allele frequency for CYP3A4*18 in the Korean cohort, and a 2024 Sri Lankan pharmacogenomics survey recorded a frequency of ~0.1%, consistent with the near-absence seen in South and European populations. Heart transplant pharmacokinetic models in Chinese cohorts have incorporated this variant as a significant covariate for tacrolimus clearance.

The overall evidence level is moderate: findings are replicated across independent cohorts and multiple drug classes, the biological mechanism is plausible, and the variant is analytically clean (rare, well-characterized missense change). However, no large prospective randomized trials or CPIC/DPWG guidelines exist specifically for this allele.

Practical Actions

For the vast majority of people worldwide, this variant is absent and no action is needed. For carriers — especially those of East Asian ancestry — the implications depend on which CYP3A4-metabolized drugs are prescribed.

For narrow therapeutic index drugs like tacrolimus, cyclosporine, and carbamazepine, reduced CYP3A4 activity means slower clearance: standard doses can produce supratherapeutic blood levels, raising toxicity risk. Therapeutic drug monitoring becomes especially important. For warfarin, the pharmacogenomics team should consider rs28371759 status alongside the dominant CYP2C9 and VKORC1 variants when modeling dose requirements.

The compounding effect of carrying rs28371759 alongside CYP3A4*22 (rs35599367) or CYP3A5*3/*3 (rs776746) is clinically important: these variants converge on the same metabolic pathway, and combined carriers may have substantially greater reductions in total CYP3A clearance than any single variant predicts.

Interactions

CYP3A4 rs28371759 interacts with the CYP3A metabolic axis:

CYP3A4*22 (rs35599367): This established decreased-function allele reduces CYP3A4 mRNA expression ~50%. Carriers of both rs28371759 (reduced protein function) and CYP3A4*22 (reduced protein quantity) would have severely diminished total CYP3A4 capacity. The combined recommendation for tacrolimus dosing should weight the established CYP3A4*22 guideline as primary, with rs28371759 as an additional signal for close monitoring.

CYP3A5*3 (rs776746): CYP3A5 non-expressers (*3/*3) already lack the CYP3A5 backup pathway. An rs28371759 carrier who is also CYP3A5*3/*3 (very common in Europeans) has reduced CYP3A4 activity with no CYP3A5 to compensate — these individuals are at greatest risk of accumulating tacrolimus, cyclosporine, or other CYP3A substrates to toxic levels.

CYP3A4*1G (rs2242480): This intronic variant reduces both CYP3A4 and CYP3A5 expression ~30% and is common in East Asian populations where rs28371759 also reaches actionable frequency. Co-occurrence of both alleles in the same individual would represent additive reductions in CYP3A metabolic capacity.

Your IRS1 (Insulin Receptor Substrate 1) gene encodes the first protein activated when insulin binds to its receptor on cell surfaces. Think of it as the ignition switch for your entire insulin signaling system¹¹ IRS1 is phosphorylated by the insulin receptor and then activates downstream pathways like PI3K/AKT that control glucose uptake, glycogen synthesis, and protein metabolism. This variant sits approximately 500 kb upstream of IRS1 and regulates how much IRS1 protein your muscle cells produce.

The Mechanism

The C allele at rs2943641 reduces IRS1 protein levels in skeletal muscle by approximately 30% and decreases insulin-stimulated phosphatidylinositol-3-OH kinase (PI3K) activity²² PI3K is the lipid kinase that IRS1 recruits after phosphorylation — it generates PIP3, which activates AKT to trigger GLUT4 translocation and glucose uptake. With less IRS1 protein available, insulin's signal gets dampened right at the source. Your pancreas compensates by secreting more insulin (hyperinsulinemia), but your muscles and liver remain relatively resistant to insulin's effects.

This creates a vicious cycle: higher insulin levels → more fat storage → more insulin resistance → even higher insulin. Breaking this cycle requires optimizing your diet to minimize insulin demand.

The Evidence

The original discovery GWAS³³ original discovery GWAS
Rung et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet, 2009 identified rs2943641 in 14,358 European participants with an odds ratio of 1.19 for type 2 diabetes per C allele (P = 9.3 × 10⁻¹²). Functional studies confirmed the C allele's association with reduced IRS1 protein and impaired PI3K activity in human muscle biopsies.

The POUNDS LOST trial⁴⁴ POUNDS LOST trial
Qi et al. IRS1 gene variation modifies insulin resistance response to weight-loss diets. Circulation, 2011 randomized 738 adults to four diets varying in macronutrient content for 2 years. At 6 months, CC carriers on the highest-carbohydrate diet (65% carbs, 20% fat) showed greater improvements in insulin resistance (HOMA-IR decreased by 0.27 vs 0.01 for CT/TT, P=0.009) and lost more weight (6.5 kg vs 4.5 kg, P=0.015). On the lowest-carbohydrate diet (35% carbs, 40% fat), the pattern reversed — non-CC carriers did better. This gene-diet interaction was significant (P<0.05) and persisted at 2 years for HOMA-IR (P=0.023).

A four-population vitamin D study⁵⁵ four-population vitamin D study
Powe et al. Circulating 25-hydroxyvitamin D, IRS1 variant rs2943641, and insulin resistance. Clin Chem, 2014 in 3,065 women found a striking gene-nutrient interaction: higher vitamin D levels (25(OH)D) reduced insulin resistance only in TT homozygotes, not in C carriers. For every 10 ng/ml increase in vitamin D, TT carriers saw HOMA-IR drop by 8% (pooled β = −0.008, P=0.004). This interaction was consistent across Boston Puerto Rican, Framingham Offspring, CARDIA, and Nurse's Health Study II cohorts and was female-specific.

Lipid effects⁶⁶ Lipid effects
Bacci et al. The type 2 diabetes and insulin-resistance locus near IRS1 is a determinant of HDL cholesterol and triglycerides. Atherosclerosis, 2011 examined 2,037 diabetic subjects and found each C allele decreased HDL cholesterol by 1 mg/dl (P=0.0045) and increased triglycerides by 6 mg/dl (P=0.018), independent of BMI.

Practical Implications

This variant creates a metabolic fork in the road. If you have the CC genotype, a higher-carbohydrate, lower-fat diet (Mediterranean or plant-based) improves insulin sensitivity more than a low-carb or ketogenic approach. The mechanism: lower dietary fat means less intramyocellular lipid accumulation, which would otherwise further impair the already-compromised insulin signaling.

For CT and TT genotypes, dietary flexibility is greater, though TT carriers uniquely benefit from optimizing vitamin D status.

Interactions

This variant interacts with dietary macronutrients in a sex-specific manner. A two-population study⁷⁷ A two-population study
Qi et al. Modulation by dietary fat and carbohydrate of IRS1 association with type 2 diabetes traits. Diabetes Care, 2013 found the protective T allele reduced T2D risk only in women with low carbohydrate intake and in men with low fat intake — suggesting men and women with this variant may need different macronutrient strategies.

The rs2943641 variant is in strong linkage disequilibrium with rs7578326 (both track together) and is independent of the IRS1 coding variant rs1801278 (G972R), which is 567 kb away.

For cancer risk, the SOS cohort⁸⁸ SOS cohort
Carlsson et al. The IRS1 rs2943641 variant and risk of future cancer among morbidly obese individuals. JCEM, 2013 found T allele carriers had lower cancer incidence, but only among individuals with BMI >40. This suggests the metabolic protection from lower insulin resistance translates to reduced cancer risk in the most insulin-resistant populations.